- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01552434
Bevacizumab og Temsirolimus alene eller i kombination med valproinsyre eller cetuximab til behandling af patienter med avanceret eller metastatisk malignitet eller anden godartet sygdom
Et fase I-forsøg med Bevacizumab, Temsirolimus alene og i kombination med valproinsyre eller Cetuximab hos patienter med avanceret malignitet og andre indikationer
This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body or other disease that is not cancerous. Immunotherapy with bevacizumab and cetuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bevacizumab and temsirolimus work better when given alone or with valproic acid or cetuximab in treating patients with a malignancy or other disease that is not cancerous.
Studieoversigt
Status
Betingelser
- Castlemans sygdom
- Lymfangioleiomyomatose
- Karcinom i fordøjelsessystemet
- Ondartet neoplasma
- Tilbagevendende brystkarcinom
- Tilbagevendende skjoldbruskkirtelcarcinom
- Metastatisk Urothelial Carcinom
- Malignt kvindeligt reproduktionssystem neoplasma
- Neurofibromatose type 2
- Tilbagevendende bløddelssarkom hos voksne
- Metastatisk malign neoplasma
- Erdheim-Chesters sygdom
- Malignt luftvejsneoplasma
- Ondartet thoraxneoplasma
- Stage IV brystkræft AJCC v6 og v7
- Avanceret malignt neoplasma
- Tilbagevendende malign neoplasma
- Ildfast malignt neoplasma
- Fase III brystkræft AJCC v7
- Fase IIIA Brystkræft AJCC v7
- Fase IIIB Brystkræft AJCC v7
- Stage IIIC brystkræft AJCC v7
- Tilbagevendende bløddelssarkom i barndommen
- Neoplasma af blødt væv
- Læbe- og mundhulekarcinom
- Ondartet endokrin neoplasma
- Malignt mandligt reproduktionssystem neoplasma
- Malignt urinvejs-neoplasma
- Mesothelial neoplasma
- Tilbagevendende karcinom i fordøjelsessystemet
- Tilbagevendende karcinom i det kvindelige reproduktive system
- Tilbagevendende karcinom i mandligt reproduktionssystem
- Tilbagevendende pharynxcarcinom
- Fase III svælgkræft
- Fase IV svælgkræft
- Stadie IVA Faryngeal kræft
- Stadie IVB Farynxkræft
- Stadie IVC Pharyngeal Cancer
- Thyroid Gland Neoplasma
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of treatment with bevacizumab and temsirolimus in combination and plus valproic acid or cetuximab.
SECONDARY OBJECTIVES:
I. Preliminary descriptive assessment of anti-tumor efficacy of each combination.
II. Preliminary assessment of the pharmacokinetic, pharmacodynamic markers of target inhibition and correlates of response (optional).
OUTLINE: This is a dose-escalation study of bevacizumab and temsirolimus. Patients are assigned to 1 of 3 treatment groups.
GROUP I: Patients receive temsirolimus intravenously (IV) over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22.
GROUP II: Patients receive temsirolimus and bevacizumab as in Group I and valproic acid orally (PO) daily on days 1-7 and 15-21.
GROUP III: Patients receive temsirolimus and bevacizumab as in Group I.
In all groups, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- M D Anderson Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients with advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or have no standard therapy that induces a complete response of at least 10% or improves survival by at least three months; in addition, patients with disease that are "benign" by pathology, but relentlessly progressive, leading to disability, pain, and premature death in the majority of cases (including, but not limited to lymphangioleiomyomatosis [LAM], type 2 neurofibromatosis [NF], Erdheim Chester disease, and Castleman's disease) may also be considered for enrollment
- Patients should be at least four weeks from the last day of therapeutic radiation or cytotoxic chemotherapy or from antibody therapy, or at least five half-lives from non-cytotoxic targeted or biologic therapy; patients may have received palliative radiation immediately before (or during) treatment provided radiation is not to the only target lesion available
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Karnofsky >= 60%
- Lansky performance status of >= 60% for participants 16 years old or younger
- Absolute neutrophil count >= 1,000/mL
- Platelets >= 50,000/mL
- Creatinine =< 3 X upper limit of normal (ULN)
- Total bilirubin =< 3.0
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 X ULN
- Fasting level of total cholesterol of no more than 350 mg/dL
- Triglyceride level of no more than 400 mg/dL
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days after the last dose
- Ability to understand and the willingness to sign a written informed consent document
- Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies
Exclusion Criteria:
- Patients with clinically significant unexplained bleeding within 28 days prior to entering the study
- Uncontrolled systemic vascular hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg on medication)
- Patients with clinically significant cardiovascular disease: History of CVA (cerebrovascular accident) within 6 months, myocardial infarction or unstable angina within 6 months, unstable angina pectoris
- Pregnant or breast-feeding women
- History of hypersensitivity to bevacizumab, murine products, or any component of the formulation
- History of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any component of the formulation
- History of hypersensitivity to cetuximab, murine products, or any component of the formulation
- Patients that are taking cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) inducers and/or inhibitors; if a patient has a history of taking CYP3A4 inducers and/or inhibitors prior to enrollment on the protocol, it is strongly recommended that the patient stops the drug and waits at least 5 half-lives of said drug before initiating therapy on protocol
- Colorectal cancer patients with known v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation (for the arm combining bevacizumab, temsirolimus and cetuximab)
- Patients who have had major surgery within 6 weeks of enrollment in the study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Group I (temsirolimus, bevacizumab, cetuximab)
Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given IV
Andre navne:
Optional correlative studies Given IV
Andre navne:
Given IV
Andre navne:
Optional correlative studies |
|
Eksperimentel: Group II (temsirolimus, bevacizumab, valproic acid)
Patients receive temsirolimus and bevacizumab as in Group I and valproic acid PO on days 1-7 and 15-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given IV
Andre navne:
Optional correlative studies Given IV
Andre navne:
Optional correlative studies Given PO
Andre navne:
|
|
Eksperimentel: Group III (temsirolimus, bevacizumab)
Patients receive temsirolimus and bevacizumab as in Group I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given IV
Andre navne:
Optional correlative studies Given IV
Andre navne:
Optional correlative studies |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Dose Limiting Toxicities (DLT)
Tidsramme: First 28-day cycle
|
A dose limiting toxicity (DLT) is defined as a clinically significant adverse event or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications and occurring during the first cycle on study that meets any of the following criteria:
|
First 28-day cycle
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Sarina A Piha-Paul, M.D. Anderson Cancer Center
Publikationer og nyttige links
Generelle publikationer
- Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26;7(17):23227-38. doi: 10.18632/oncotarget.7594.
- Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist. 2023 Dec 11;28(12):1100-e1292. doi: 10.1093/oncolo/oyad158.
- Piha-Paul SA, Tseng C, Thompson E, Stafford RJ, Le H, Kang L, Fu S, Tsimberidou A, Blumenschein G, Ahnert JR, Slopis JM, Hong D, Naing A, Meric-Bernstam F, Ng CS, Westin S, Sood AK. Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion. Oncologist. 2026 Feb 5;31(3):oyaf413. doi: 10.1093/oncolo/oyaf413.
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Sygdomme i det endokrine system
- Mundsygdomme
- Stomatognatiske sygdomme
- Sygdomme i nervesystemet
- Patologiske processer
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Mandlige urogenitale sygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Sygdomsegenskaber
- Genetiske sygdomme, medfødte
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer i hoved og hals
- Neurodegenerative sygdomme
- Neoplasmer, kirtel og epitel
- Neoplastiske processer
- Hudsygdomme
- Brystsygdomme
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Karcinom
- Otorhinolaryngologiske sygdomme
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Heredodegenerative lidelser, nervesystem
- Nerveskede neoplasmer
- Neoplastiske syndromer, arvelig
- Neurokutane syndromer
- Neuroendokrine tumorer
- Øresygdomme
- Otorhinolaryngologiske neoplasmer
- Pharyngeale sygdomme
- Neoplasmer, bindevæv og blødt væv
- Sygdomme i kranienerve
- Skjoldbruskkirtelsygdomme
- Neurom
- Neoplasmer i kranienerve
- Vestibulocochleære nervesygdomme
- Retrocochleære sygdomme
- Histiocytose, ikke-langerhans-celle
- Neurofibrom
- Lymfangiomyom
- Perivaskulær epiteloid celle neoplasmer
- Neurom, akustisk
- Neurilemma
- Histiocytose
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Patologiske tilstande, tegn og symptomer
- Hud- og bindevævssygdomme
- Hemiske og lymfatiske sygdomme
- Neurofibromatoser
- Neoplasma, lymfet væv
- Neoplasmer
- Tilbagevenden
- Brystneoplasmer
- Neoplasma Metastase
- Sarkom
- Urologiske neoplasmer
- Castlemans sygdom
- Mundens neoplasmer
- Carcinom, overgangscelle
- Thyroidneoplasmer
- Lymfangioleiomyomatose
- Neurofibromatose 2
- Neoplasmer i blødt væv
- Pharyngeale neoplasmer
- Neoplasmer, mesotheliale
- Erdheim-Chesters sygdom
- Neoplasmer i endokrine kirtler
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovlforbindelser
- Organiske kemikalier
- Fedtsyrer
- Lipider
- Syrer, acyklisk
- Carboxylsyrer
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Uorganiske kemikalier
- Pentanesyrer
- Valerates
- Fedtsyrer, flygtige
- Makrolider
- Lactoner
- Immunoglobulin -isotyper
- Sulfider
- Anioner
- Ioner
- Elektrolytter
- Hydrogensulfid
- Bevacizumab
- Cetuximab
- Sirolimus
- Immunoglobulin G
- Valproinsyre
- Disulfider
- temsirolimus
Andre undersøgelses-id-numre
- 2012-0061
- 2012-0061 (Anden identifikator: M D Anderson Cancer Center)
- NCI-2012-00347 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .